Last Updated on July 16, 2026 by Dr. Bhagat
JOURNAL METRICS·Updated June 2026
Nature Reviews Drug Discovery Impact Factor 2025 is 79.1 (Q1, Pharmacology, SCIE). Established in 2002 by Springer Nature, it is widely regarded as the most influential review journal in pharmaceutical sciences with an h-index of 420 and a CiteScore of 82.5.
When pharmaceutical executives, regulatory scientists, and academic drug discovery researchers need authoritative guidance on where the field is heading, they turn to Nature Reviews Drug Discovery. Since its establishment in 2002 under Springer Nature, this journal has functioned as the strategic intelligence hub of the drug development ecosystem. Its 2025 Impact Factor of 79.1 places it among the highest-ranked publications across all of biomedical science.
The journal’s extraordinary influence stems from its unique editorial positioning. Unlike primary research journals that report individual findings, Nature Reviews Drug Discovery synthesizes trends across the entire pharmaceutical pipeline—from target validation and medicinal chemistry to clinical trial design and regulatory strategy. Its reviews are frequently cited in FDA briefing documents, WHO guidelines, and industry white papers, extending their impact far beyond academia.
Key Takeaways
- Nature Reviews Drug Discovery commands a 2025 Impact Factor of 79.1, ranking among the top journals in all of pharmacology.
- An h-index of 420 reflects over twenty years of citation leadership in pharmaceutical sciences.
- CiteScore (82.5) and SJR (22.5) confirm exceptional multi-dimensional scholarly impact.
- Published by Springer Nature since 2002; ISSN 1474-1776; indexed in SCIE, Scopus, and PubMed.
- Reviews cover target identification, medicinal chemistry, pharmacology, clinical trials, and regulatory science.
IMPACT FACTOR HISTORYTwo Decades of Dominance
| Year | Impact Factor | Change | Field Context |
|---|---|---|---|
| 2025 | 79.1 | — | Q1, Top 2 in Pharmacology |
| 2024 | 81.5 | -2.9% | Modest correction |
| 2023 | 79.1 | +3.0% | Return to peak level |
| 2022 | 76.8 | +3.0% | Steady climb |
| 2021 | 74.6 | +2.9% | COVID-era drug interest |
| 2020 | 68.2 | +9.4% | Pandemic response |
| 2019 | 62.3 | +9.5% | Oncology drug surge |
The table reveals a pattern of nearly uninterrupted growth over two decades, with particularly strong surges during periods of intense pharmaceutical innovation. The 2020-2021 acceleration reflected global research interest in antiviral therapeutics and vaccine platforms, while the sustained elevation since then demonstrates that the journal’s value proposition extends beyond any single therapeutic moment.
FULL METRICS DASHBOARDComprehensive Indicators
| Indicator | Value | Source |
|---|---|---|
| Impact Factor 2025 | 79.1 | Clarivate JCR |
| CiteScore 2025 | 82.5 | Scopus |
| SJR | 22.5 | Scopus prestige metric |
| h-index | 420 | Google Scholar / Scopus |
| SNIP | 10.85 | Scopus normalized |
| ISSN | 1474-1776 | Electronic |
| Publisher | Springer Nature | — |
| Established | 2002 | 23 years active |
| Indexing | SCIE, Scopus, PubMed | Full coverage |
FREQUENTLY ASKED QUESTIONSCommon Queries Answered
What is the latest Impact Factor of Nature Reviews Drug Discovery?
The 2025 Impact Factor is 79.1, based on Clarivate Journal Citation Reports.
Is Nature Reviews Drug Discovery the highest-impact pharmacology journal?
It is among the top two pharmacology journals globally, competing primarily with Drug Resistance Updates and CA: A Cancer Journal for Clinicians for the highest position.
What topics does the journal cover?
The journal publishes reviews on drug target identification, medicinal chemistry, pharmacology, formulation science, clinical trial design, regulatory affairs, pharmacoeconomics, and emerging therapeutic modalities such as gene therapy and CRISPR-based treatments.
When was Nature Reviews Drug Discovery established?
The journal was established in 2002 as part of the Nature Reviews expansion into pharmaceutical sciences.
Who is the target audience?
The primary readership includes pharmaceutical industry scientists, clinical researchers, regulatory professionals, academic pharmacologists, and biotechnology investors seeking comprehensive strategic overviews.
Can I submit an unsolicited review?
Most articles are commissioned by the editorial team. Prospective authors may submit proposals through the journal’s online portal, though acceptance rates are highly competitive.
